RxDoctor Payments Data

Lakuma Mogili, MD

Psychiatry · Winchester, VANPI 1265491310

Payments from drug & device makers

$1,975in general payments, 2019–2025

Across 127 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$399
  • Neurocrine Biosciences, Inc.$348
  • Sunovion Pharmaceuticals Inc.$273
  • Otsuka America Pharmaceutical, Inc.$209
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$175
  • Johnson & Johnson$174
  • plus $397 from 7 others

What the payments were for

  • Food & beverage$1,975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,975 in reported general payments places this provider in the 80th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$24,658
Medicare patients
71
Services billed
401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate101$291,697
AustedoDeutetrabenazine36$226,877
Abilify MaintenaAripiprazole51$131,400
RexultiBrexpiprazole48$73,862
CaplytaLumateperone Tosylate25$44,971
LybalviOlanzapine/Samidorphan Malate19$28,915
Clozapine206$17,269
SecuadoAsenapine11$15,603
Aripiprazole116$12,463
TrintellixVortioxetine Hydrobromide26$12,298
Lurasidone Hcl60$11,942
Paliperidone ErPaliperidone60$10,385
Divalproex Sodium124$9,942
Varenicline Tartrate25$5,336
LoxapineLoxapine Succinate50$5,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$174$291,697101 claims
Teva Pharmaceuticals USA, Inc.Austedo, Loxapine$172$232,11086 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$209$205,26299 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$175$44,97125 claims
Alkermes, Inc.Lybalvi$399$28,91519 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$35$12,29826 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →